© 2007-2017, All Rights Reserved, The Macula Center, unless otherwise stated. The information provided on this website is for informational purposes only and is not intended to substitute, supplant or augment any advice from your physician or other health care professional or medication label. You should not use the information on this site for diagnosis or treatment of any eye or health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication or change your course of treatment without first consulting your physician. The Macula Center does not endorse, guarantee or make any claims for or about any products or information mentioned or linked to from this website.
Study AMD-3 was a randomized, double-masked, sham-controlled, two-year study designed to assess the safety and efficacy of LUCENTIS in patients with neovascular AMD (with or without a classic CNV component). Data are available through Month 12. Patients received LUCENTIS mg or mg intravitreal injections or sham injections once a month for 3 consecutive doses, followed by a dose administered once every 3 months for 9 months. A total of 184 patients were enrolled in this study (LUCENTIS mg, 60; LUCENTIS mg, 61; sham, 63); 171 (93%) completed 12 months of this study. Patients treated with LUCENTIS in Study AMD-3 received a mean of 6 total treatments out of a possible 6 from Day 0 through Month 12.